Dr. Thomas Schall
days listening. everyone year us call. good quarter and afternoon call. our Thank first conference Lee, Thank our to XXXX on XX joining full you you, and since just QX for been XXXX It’s
my launch; So first, main progress making I’ll checkpoint update and potential vasculitis avacopan, ever to second, we’ll our pipeline review of three in avacopan, CCXXXX, briefly our plans as immune an our drug; remarks oral we an closer in a on and our areas; today, move inhibitor. ANCA-associated for -- third,
of soon slide we held on Moving I’ll held was July start our after highlights R&D new This to April patients. on we three, with look PDUFA from as virtual Day, date which to the medication hope which our XXth. first deeply potential launch of forward to the offers was believe Xth,
with have having also for of the those live you Massie is described R&D on for his what account like to of the severe long he consequences, currently Day a and story to therapy. of a it disease powerful treatments ANCA-associated of to XXth, an only expressed reminder new is Mr. new desperate At consequences vivid each person medicine. who we for moving XX-week April the It not we Vasculitis, need give available. heard journey Speaking is an which will night. enduring and with the but mistake, rest of for our take the medicine following itself, attended information consequences shown not and then on devastating it of towards is patients data patients, delivered is diagnosis our Glen the Glen’s one slide a them who top death. period another. alternative of hope you’ll the avacopan have on endure bad as puts Vasculitis, and ANCA winding The determination, no all of eight-week that time ADVOCATE the day trial. the discussed to who will covers the illness avacopan. some ChemoCentryx successful for that treatments Make taking hope not family is of endpoints a from immediately others during scourge his often four must that each It disease stop, we until up we will we R&D current work at easy, Day, go stops Glen, only trade to not Glen of and
from subjects of period that It weeks benefit and Glomerular then a support estimated treatment after XX to EGFR, increased Rate relapses avacopan the group, or had from key stopped. to indicator treatment startup the vasculitis. notable had waning started group in avacopan studies continued of These there avacopan decline week modestly avacopan of taking may out of Filtration XXX weeks people was of efficacy to ANCA-associated of suggests XX the group. renal to in stopped with six with subjects is avacopan, which During of observations seven stopped. is avacopan idea XX, steadily a out once function, XXX therapy once again in relapses were prednisone This that the
Day Vasculitis Merkel Peter Our of Chair, out vasculitis, at the trained in and who Center R&D Merkel, also Rheumatology clinicians, University Service at laid body or too He patients Addenbrooke’s Director Hospital and to Cambridge, glucocorticoids strike disease. too can and areas Dr. Vasculitis England. of Pennsylvania; much two needs glucocorticoids. disease. ANCA-associated of unmet Lupus therapy of renowned Jayne. into ANCA-associated of developing Dr. hating for Director and threatening includes the David that the life leading world explain featured different Dr. often to the He long, which the patients vasculitis an the in in current use this Penn pointed many insidious organ
page of also quality improve life of of Dr. both we of avacopan and permanent Dr. cost for best reduce Merkel ability New vasculitis the that slide to an nearly of orphan worst. publication the it all summarized the number reduce see remarkable views, the Jayne XXth, of damage is and Not Medicine would England it the at of XX,XXX percentile in England potential a drugs pandemic. findings and ANCA-associated rare putting ADVOCATE during Jayne disease are the for Jayne Journal currently on also finding The studies. glucocorticoids New the avacopan risk organ bad article Journal reduce of Dr. care. which received have the to the a five. As articles. February put emphasized and referred Dr. relapses XXnd to then trial
XXX XX approximately not rituximab Finally, term or patients important? is the prevent a you disease in both a Dr. Why described in in without the of patients blinded another avacopan like would immunosuppressant, activity as additional trial. total did placebo period glimpse last last in help rituximab to cyclophosphamide. of in of ADVOCATE the It ADVOCATE during ADVOCATE of showed may weeks effect, the an immunosuppressant two-thirds XX This such be remind avacopan placebo-controlled this balanced trial. as relapse. for non-severe allows receive avacopan some a monotherapy COVID. sustaining helping fashion Jayne in potential longer that that plus arms the for across I weeks times avacopan’s Because, for or and the efficacy remission useful of in particularly
by for of as the the maintenance saw editorial also New when of Jayne Dr. Merkel I England from earlier. viewpoint session, is blinded Journal avacopan article, XX, need XX-week patient’s that the transform trial XX Q&A supported strong a a of all, by it, urgent. that Medicine The to novel weeks above they of two by indicated therapy, was is the through treatment, the observations is the Dr. data mentioned the testimony. data experts, happens eight both the to accompanied of made avacopan and strength the as potential the that new disease what the after case the that period and All elements the stopped, dosing on drug During and top the burden and a a weeks in patients they stop well these world’s The great therapy suggest care.
orphan only May we such Arthritis with that Advisory approved forward FDA Now meeting, an and filing disease the previous the consistently a new given to molecular a have week’s From preparing anticipated NDA been have Committee meeting. entity for one avacopan of next our and we fact look drug. is Xth
response for of in forum over patients. Our opportunity complexities shifting upside the deliberations data, its approach It risk which as hear been ANCA-associated a of believe this to from view the a also to is ANCA-associated our the meeting one agency to an the paradigm granularity clinical vasculitis. its high review knowledge hopes deliver in patients rare the ADVOCATE the treatment by And profile Adcom order the strength favorable benefit underscore potential to excellent with help course of have to disease. a down vasculitis lives alternative raised provide FDA whose and by degree the subsequent decision. of we is in to of in Committee to an the the is share a topics It significant turned
the Advisory ours, the commenting While now will have we Committee, and be is. on FDA document the FDA’s is Book received not we it but is Briefing therefore, confidential, It not the today. for
materials to the However, Adcom Adcom publicly the briefing do available the we date. expect FDA before meeting make
start pressure expected any We normal test FDA as the to be for Adcom FDA would meeting.
our the understanding how may to trial our benefit Day, As profile. the discussions we forward In trial information assumptions, address Adcom historical include questions. ADVOCATE FDA statistical and look design, we believe, treated, R&D that our reviews based to ANCA-associated safety is and perspectives during Phase said topics with on the we expanding III the risk vasculitis FDA presentations,
of confident consistently impending entering Accordingly, anticipated following will of in activities. confidence meeting, outcome of light secondary are conclusion clinically call signals of We meaningful in avacopan the that primary this earnings this in into a we period today’s We quiet meeting. have and favor endpoint approach. In therapy. the Adcom the believe we be
of briefing that and understand will will on further until appreciate of not and on conclusion Xth. meeting can the We Adcom upon its have likely we availability we after materials. questions ahead appreciate While questions you week’s the commenting additional be have May that will hope likely next you
preparations our to for now launch. Turning potential
During R&D Day Chief Tosh Officer, our summarized Butt commercial plans. our Operating
reported XX% prescribe at sell in of extremely surveyed, illustrated avacopan compelling, avacopan moderately indicating potential finding look market sell. nephrologist six, XXX% the the if either approved interest by them, of or rheumatologists the of and XXX with data you Tosh they FDA market them, on research and primary that all would If that slide avacopan,
side priority effects Asked need a who about seen to ANCA in the choose XX% was XX% as safety, interesting compared experts, top to better fewer vasculitis, of better for see greatest these is that it efficacy. unmet
comprising slide vasculitis, see physicians, can from with seven. of other In specialists ANCA nephrologist, research study of was treat market which you a XXX mainly rheumatologists who and As handful a see some impression positive a then of heard conducted in can April XXXX, months of the profile. released XX% of its that after data, had and we had XX% is, you avacopan
online running and at ANCA-associated raising in of are Congresses. We Rethink print relevant ANCA vasculitis disease journals rethinkanca.com campaign, the now our profile through awareness at
We proposition are are still to the for new building have to avacopan with to typically pre-approval covering vasculitis held exchange support XX% to payers ongoing. patient a population, roughly individual, XX a takes and receptive high to six which months avacopan’s electronic listed help information value patients launch, Payers also of months ANCA-associated formulary. States United we is it since obtain capability access after medications on process be
patient form class who relapsing most, are world that for Turning diagnosed of or are way is in the to our disease. X,XXX patients, eligible commercial initially well the or on capability. whom those to life slide segments. are organ addressable newly threatening eight, up building United That we In States it we to is about short, patients a need estimate who namely XX,XXX avacopan population with
a We Xth. PDUFA the ready be rapid will launch after approved July if for of date
law. of half making [ph] second ahead Japan also net potential on Pharma partner of Our expected would Vifor and royalties in of the plans decisions sales pay aggregate teams is sales one with Europe us off the in XXXX. regulatory from Vifor mid-XX%s commercialization
vasculitis As ANCA-associated is the avacopan. for you can see start from just slide nine,
moving other orphan as we with forward turn pipeline-in-a-drug are into We seek disease avacopan on multiple fronts indications. a to
HS. First, slide XX shows our Suppurativa or Hidradenitis skin plans disorder of debilitating
HS. track this year to trial launch Phase are by of pivotal in III end patients avacopan with on of a severe the We
most trial of could patients clinical early-stage HS, severe compared called, placebo AURORA in II demonstrated weeks XX three the so after to that Phase a significant Our form therapy. the of of improvement provide avacopan
an for out patients and II them. will we have data we when report Phase these following weeks are XX additional those We
high avacopan, is the another AURORA somewhere The have trial Response for will XX,XXX expect score since arms. two XXX study, open-label a disease. Suppurativa potential and it of to We early-stage or months blinded patients continuing Phase consistent up. with patients indication HS at the enroll III weeks three blockbuster randomized divided with estimated be to follow against the Hidradenitis with XX,XXX placebo into for primary XX the with the an six total Clinical endpoint XXX period Phase U.S. II measured Score in to between
drug early-stage poster We for session in for too have scheduled at avacopan a are Note for designation May. for Society we in the orphan filed three that Investigative patients. Dermatology
randomized the like gold patients Filtration arm. Rate nephrologists measuring standard the seen kidney the trial an we disease, for slide of has this avacopan in shown EGFR rare as background CX in Moving a most Glomerular function Estimated demonstrated in important would CXG. back placebo to Glomerulopathy, finding medication is top renal by of previously results disease never ACCOLADE in or to included journal on our for stark in functions a a the of in contrast publish and been controlled plan as to finding significant improvement kidney regard nephrology what which XX. Avacopan very measured trials
We of the of agency, using the treatment CXG. XX in FDA are the from CX the new the observations our XX Index. to new reported ACCOLADE Chronicity the benefit trial Disease to At of Day, with week clinical we some with in for discuss meeting preparing avacopan evidence R&D
nephritis XX As but assessed improving a which and achieved EGFR, benefits, resting first the therapy lupus other can function over the score in study, these kidney currently a depicted of need effect second the with as the typically avacopan. also on shows, kidneys vasculitis. This chronicity is clinical promising lupus hope has weeks fibrosis into the the a the such therapy patient only immunosuppression an nephritis, units, diseases used provides clinical second in on placebo avacopan to patients might sign the in broad to than crossed so control an as the glomeruli. offer targeted avacopan the LN Avacopan too of other patients effort to XX. ANCA after that filtration chance with during an patients We is of placebo patients in or This by for slide for slide great. lead is as introduce graphic limited being in kidney which destruction, scarring renal Current suggests This declined rose significance more is in the disease. that the around statistical trial, development avacopan to half. XX
next-generation about slide oral words we as CCXXXX. Finally, to few turn XX, a checkpoint inhibitor plans for our
Current featured noted to safety on antibody lung significantly be patients Pneumonitis profound with a example, in Association contributed was based As XX, Research the immunotherapies meeting session but slide American poster can for non-small treated cancer Cancer cancer at CCXXXX in without not for antibody earlier cell this treatment, always immunotherapy. have month. consequences.
our than may active R&D As inhibitor Day better a then on Slide the to its preclinical on evaluate stage April environment development clinical to lab pathway remission and that data and of an shrinking vivo. antibody suggests how CCXXXX PD-LX/PD-X our plan tumor we proposition. tumor value to XXth, outlines orally molecule, our next as XX small show it excellent during in and in data the results CCXXXX discussed take tumor penetrate
Ib a cancer initiate to later quarter. the to to patients our position. expect outline now in this the over Phase I strength will turn financial of We Susan call trial
